prnewswire.com · 16 jul

Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain

Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹ GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management.

zacks.com · 10 jul

Medtronic (MDT) Exceeds Market Returns: Some Facts to Consider

Medtronic (MDT) reached $83.87 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

seekingalpha.com · 10 jul

Medtronic: Undervalued, And The Tailwinds Are Just Getting Started

I initiate coverage on Medtronic, highlighting its status as a leading medtech name with premium margins. MDT offers an attractive diversification opportunity, combining consistent performance with accelerated revenue growth. The stock trades at undervalued levels, supporting a long-term bullish thesis and a defensive investment approach.

seekingalpha.com · 10 jul

Medtronic: Guidance Built To Be Beaten - Buy

Medtronic plc is rated buy with a $92 price target, reflecting conservative fiscal 2027 guidance and resilient growth platforms. Fiscal 2026 delivered $36.4B in revenue, the strongest growth in a decade, led by Cardiovascular and ablation solutions outpacing market rates. Guidance for fiscal 2027 excludes potential catalysts—MiniMed separation, tariff refunds, and Blackstone payment relief—implying room for upside surprises.

seekingalpha.com · 9 jul

Medtronic: A Near Decade High Dividend For This Aristocrat

Medtronic is a dividend aristocrat with a near-decade high yield, making it an attractive long-term income opportunity. The company is experiencing strong revenue growth, driven by its leading positions in cardiovascular and neuroscience medical devices. While current free cash flow payout ratios are sustainable, investors should monitor future dividend growth rates closely.

fool.com · 7 jul

3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.

zacks.com · 3 jul

Why Is Medtronic (MDT) Up 1.5% Since Last Earnings Report?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

zacks.com · 30 jun

Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know

Medtronic (MDT) reached $78.23 at the closing of the latest trading day, reflecting a -3.34% change compared to its last close.